Biohaven Pharma (BHVN) Prices 5.26M Share Offering at $47.50/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $68 at JPMorgan
October 3, 2024 6:01 AM EDTJPMorgan analyst Tessa Romero raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $68.00 (from $55.00) while maintaining a Overweight rating.
The analyst comments "We are updating our model following Biohavens updates last week around their troriluzole program in spinocerebellar ataxia (SCA), where the company expects to complete resubmission of an NDA for the treatment of all SCA genotypes... More
